2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

Confirm Password

About Us
Team
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos

December 11, 2020

0 Comments

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Rel…

Feat. B. Derman

14:16

2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do Tri…

Feat. K. Anderson

05:09

Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples

23:44

UAB Hematology Review 2021

Updates on R/R MM: Is PFS Improved With KdD vs. Kd, IKd vs. Kd, Isa-Pd vs.…

Feat. K. Godby

12:53

2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli

14:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achi…

Feat. T. Martin

30:19

SOHO Italy 1st School of Multiple Myeloma

Present & Near Future of R/R MM: Post-Bortezomib, Post-Lenalidomide, Selin…

Feat. C. Cerchione

26:18

Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequen…

08:15

2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein

25:51

KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah

13:23

Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

22:47

UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussion…

Feat. M. Leukam

23:48

UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Resul…

Feat. J. Jasielec

09:00

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja

15:22

SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…

Feat. M. Claudio Da Via

12:16

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos

12:03

Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

09:50

Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

06:21

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in Im…

Feat. F. Anwer

19:41

Peter Voorhees

Login

Login

Join VuMedi

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

Related Content